FDA and CDC field media questions regarding Johnson and Johnson vaccine pause Leaders with the Centers for Disease Control and Prevention teamed up with those heading up the U.S. Food and Drug Administration today to field reporters from across the nation after issuing a joint recommendation for a pause in the use of the Johnson and Johnson vaccine out of an abundance of caution this morning. Six in 6.8 million, the number of reported cases of people in the U.S. who developed dangerous blood clots after receiving the Johnson and Johnson COVID-19 vaccine, prompting the CDC and FDA to take swift action Tuesday out of an abundance of caution. Acting FDA Commissioner Janet Woodcock said, “This morning the FDA and CDC announced that out of an abundance of caution we’re recommending a pause of the Johnson & Johnson COVID-19 vaccine due to reports of six cases of a rare and severe type of blood clot following vaccine administration. We’re recommending this pause while we work together to fully understand these events.”